Gilead Sciences Inc (GILD)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ
Market Cap: $208.48B
Last updated: Nov 17, 2026 at 11:06 AM ET
Gilead Sciences Inc (GILD) Earnings: Report Dates and Results
Gilead Sciences (GILD) is expected to report earnings on Feb 8, 2027. In the quarter ended Sep 30, 2026, Gilead Sciences reported EPS of $2.55, above the $2.17 estimate. It beat the EPS estimate in each of the last 11 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
GILD has an expected report date of Feb 8, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 34.4% below the $1.86 reported for the quarter ended Dec 31, 2025.
GILD Earnings Call
The latest GILD earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, GILD beat 30 and missed 10. Revenue for the quarter ended Sep 30, 2026 was $8.30B, up 6.8% from $7.77B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $2.55 | $2.17 | $1.99 - $2.36 | +17.51% | Beat | +3.2% | 22 | 5 up, 2 down | Oct 29, 2026 | $8.30B |
| Jun 30, 2026 | -$6.75 | -$7.07 | -$7.93 - -$6.40 | +4.53% | Beat | -435.8% | 23 | 8 up, 4 down | Aug 3, 2026 | $7.80B |
| Mar 31, 2026 | $2.03 | $1.91 | $1.74 - $2.06 | +6.28% | Beat | +12.2% | 24 | 5 up, 6 down | May 7, 2026 | $6.96B |
| Dec 31, 2025 | $1.86 | $1.81 | $1.60 - $2.16 | +2.76% | Beat | -2.1% | 21 | 1 up, 10 down | Feb 10, 2026 | $7.92B |
| Sep 30, 2025 | $2.47 | $2.14 | $1.96 - $2.37 | +15.42% | Beat | +22.3% | 22 | 4 up, 6 down | Oct 30, 2025 | $7.77B |
| Jun 30, 2025 | $2.01 | $1.95 | $1.86 - $2.05 | +3.08% | Beat | 0.0% | 23 | 9 up, 3 down | Aug 7, 2025 | $7.08B |
| Mar 31, 2025 | $1.81 | $1.78 | $1.60 - $2.11 | +1.69% | Beat | N/A | 17 | 1 up, 4 down | Apr 24, 2025 | $6.67B |
| Dec 31, 2024 | $1.90 | $1.70 | $1.13 - $2.16 | +11.73% | Beat | +10.5% | 20 | 2 up, 3 down | Feb 11, 2025 | $7.57B |
| Sep 30, 2024 | $2.02 | $1.55 | $1.33 - $1.92 | +30.32% | Beat | -11.8% | 20 | 4 up, 0 down | Nov 6, 2024 | $7.54B |
| Jun 30, 2024 | $2.01 | $1.60 | $1.36 - $1.80 | +25.63% | Beat | +50.0% | 22 | 7 up, 0 down | Aug 8, 2024 | $6.95B |
| Mar 31, 2024 | -$1.32 | -$1.52 | -$1.86 - -$1.14 | +13.16% | Beat | -196.4% | 15 | 0 up, 3 down | Apr 25, 2024 | $6.69B |
| Dec 31, 2023 | $1.72 | $1.76 | $1.59 - $2.04 | -2.27% | Miss | +3.0% | 23 | 3 up, 4 down | Feb 6, 2024 | $7.11B |
| Sep 30, 2023 | $2.29 | $1.92 | $1.62 - $1.97 | +19.27% | Beat | +20.5% | 22 | 3 up, 3 down | Nov 7, 2023 | $7.05B |
| Jun 30, 2023 | $1.34 | $1.64 | $1.47 - $1.88 | -18.29% | Miss | -15.2% | 23 | 0 up, 1 down | Aug 3, 2023 | $6.60B |
| Mar 31, 2023 | $1.37 | $1.54 | $1.24 - $1.97 | -11.04% | Miss | -35.4% | 22 | 4 up, 2 down | Apr 27, 2023 | $6.35B |
| Dec 31, 2022 | $1.67 | $1.51 | $1.16 - $1.72 | +10.60% | Beat | +142.0% | 22 | 3 up, 2 down | Feb 2, 2023 | $7.39B |
| Sep 30, 2022 | $1.90 | $1.43 | $1.16 - $1.75 | +32.87% | Beat | -28.3% | 23 | 2 up, 5 down | Oct 27, 2022 | $7.04B |
| Jun 30, 2022 | $1.58 | $1.52 | $1.29 - $1.73 | +3.95% | Beat | -15.5% | 22 | 7 up, 2 down | Aug 2, 2022 | $6.26B |
| Mar 31, 2022 | $2.12 | $1.81 | $1.38 - $2.17 | +17.13% | Beat | +1.9% | 21 | 5 up, 1 down | Apr 28, 2022 | $6.59B |
| Dec 31, 2021 | $0.69 | $1.59 | $1.21 - $2.14 | -56.60% | Miss | -68.5% | 21 | 9 up, 0 down | Feb 1, 2022 | $7.24B |
| Sep 30, 2021 | $2.65 | $1.78 | $1.49 - $2.16 | +48.88% | Beat | +25.6% | 20 | N/A | Oct 28, 2021 | $7.42B |
| Jun 30, 2021 | $1.87 | $1.75 | $1.50 - $1.97 | +6.86% | Beat | +68.5% | 22 | N/A | Jul 29, 2021 | $6.22B |
| Mar 31, 2021 | $2.08 | $2.11 | $1.71 - $2.57 | -1.42% | Miss | +23.8% | 21 | N/A | Apr 29, 2021 | $6.42B |
| Dec 31, 2020 | $2.19 | $2.15 | $2.02 - $2.33 | +1.86% | Beat | +68.5% | 19 | N/A | Feb 4, 2021 | $7.42B |
| Sep 30, 2020 | $2.11 | $1.89 | $1.65 - $2.65 | +11.64% | Beat | +20.6% | 24 | N/A | Oct 28, 2020 | $6.58B |
| Jun 30, 2020 | $1.11 | $1.45 | $1.13 - $1.84 | -23.45% | Miss | -39.0% | 24 | N/A | Jul 30, 2020 | $5.14B |
| Mar 31, 2020 | $1.68 | $1.56 | $1.44 - $1.82 | +7.69% | Beat | -4.5% | 24 | N/A | Apr 30, 2020 | $5.55B |
| Dec 31, 2019 | $1.30 | $1.67 | $1.46 - $1.85 | -22.16% | Miss | -9.7% | 24 | N/A | Feb 4, 2020 | $5.88B |
| Sep 30, 2019 | $1.75 | $1.73 | $1.53 - $1.92 | +1.16% | Beat | -4.9% | 23 | N/A | Oct 24, 2019 | $5.60B |
| Jun 30, 2019 | $1.82 | $1.71 | $1.50 - $1.89 | +6.43% | Beat | -4.7% | 24 | N/A | Jul 30, 2019 | $5.68B |
| Mar 31, 2019 | $1.76 | $1.60 | $1.41 - $1.73 | +10.00% | Beat | +18.9% | 24 | N/A | May 2, 2019 | $5.28B |
| Dec 31, 2018 | $1.44 | $1.69 | $1.44 - $2.13 | -14.79% | Miss | -19.1% | 22 | N/A | Feb 4, 2019 | $5.79B |
| Sep 30, 2018 | $1.84 | $1.63 | $1.55 - $1.86 | +12.88% | Beat | -18.9% | 21 | N/A | Oct 25, 2018 | $5.60B |
| Jun 30, 2018 | $1.91 | $1.56 | $1.46 - $1.70 | +22.44% | Beat | -25.4% | 20 | N/A | Jul 25, 2018 | $5.65B |
| Mar 31, 2018 | $1.48 | $1.67 | $1.47 - $1.86 | -11.38% | Miss | -33.6% | 21 | N/A | May 1, 2018 | $5.09B |
| Dec 31, 2017 | $1.78 | $1.67 | $1.29 - $2.00 | +6.59% | Beat | -34.1% | 22 | N/A | Feb 6, 2018 | $5.95B |
| Sep 30, 2017 | $2.27 | $2.13 | $1.92 - $2.30 | +6.57% | Beat | -17.5% | 22 | N/A | Oct 26, 2017 | $6.51B |
| Jun 30, 2017 | $2.56 | $2.17 | $1.91 - $2.34 | +17.97% | Beat | -16.9% | 19 | N/A | Jul 26, 2017 | $7.14B |
| Mar 31, 2017 | $2.23 | $2.28 | N/A | -2.19% | Miss | -26.4% | N/A | N/A | May 2, 2017 | $6.50B |
| Dec 31, 2016 | $2.70 | $2.60 | N/A | +3.85% | Beat | -18.7% | N/A | N/A | Feb 7, 2017 | $7.32B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $8.15, up 76.8% from the year before. It was $11.56 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $8.15 | +76.8% |
| Dec 31, 2024 | $4.61 | -31.4% |
| Dec 31, 2023 | $6.72 | -7.6% |
| Dec 31, 2022 | $7.27 | N/A |
| Dec 31, 2021 | $7.29 | +2.8% |
| Dec 31, 2020 | $7.09 | +6.9% |
| Dec 31, 2019 | $6.63 | N/A |
| Dec 31, 2018 | $6.67 | -24.5% |
| Dec 31, 2017 | $8.84 | -23.5% |
| Dec 31, 2016 | $11.56 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,700 words across 18 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,733 | 18 | |
| 2026Q2 | Jun 30, 2026 | 7,641 | 19 | |
| 2026Q1 | Mar 31, 2026 | 8,529 | 19 | |
| 2025Q4 | Dec 31, 2025 | 8,690 | 17 | |
| 2025Q3 | Sep 30, 2025 | 8,006 | 22 | |
| 2025Q2 | Jun 30, 2025 | 7,917 | 16 | |
| 2025Q1 | Mar 31, 2025 | 9,210 | 23 | |
| 2024Q4 | Dec 31, 2024 | 4,017 | 17 |
2026Q3 Earnings Call
Opening remarks
Jacquie Ross Senior Vice President, Treasurer and Head of Investor Relations Thank you, Rebekah. Just after market closed today, we issued a press release with earnings results for the third quarter of 2026. The press release, slides and supplementary data are available on the Investors section of our website at gilead.com. The speakers on today's call will be our Chairman and Chief Executive Officer, Daniel O'Day; our Chief Commercial and Corporate Affairs Officer, Johanna Mercier; our Chief Medical Officer, Dietmar Berger; and our Chief Financial Officer, Andrew Dickinson. After that, we'll open the call to Q&A, where the team will be joined by Cindy Perettie, the Executive Vice President of Kite. Let me remind you that we will be making forward-looking statements. Please refer to Slide 2 regarding the risks and uncertainties relating to forward-looking statements that could cause actual results to differ materially. With that, I'll turn the call over to Dan.
Daniel O'Day Chairman and Chief Executive Officer Thank you, Jacquie, and thanks, everyone, for joining us on today's call. Gilead delivered an exceptional third quarter that highlights the strength, breadth and durability of the business. Third quarter base business sales were up 16% year-over-year, Gilead's strongest growth in more than a decade, driven by Biktarvy, Descovy and Yeztugo in HIV, Trodelvy in metastatic breast cancer, and Livdelzi in PBC. At the same time, we continue to advance our diverse pipeline as we prepare for the next phase of launches. In HIV, we continue to lead across treatment and prevention. In the third quarter, HIV sales grew 18% year-over-year. Biktarvy achieved an all-time high U.S. market share, and we had a modest initial contribution from Bixlenvo, which launched in August. HIV prevention sales nearly doubled year-over-year. As expected, Yeztugo has rapidly established itself as the leading long-acting injectable option for HIV prevention. Yeztugo and Descovy for PrEP combined have 50% market share today and a $4 billion annual run rate. As Dietmar will cover later, we believe we have the most comprehensive and diverse HIV pipeline in the industry as well as in Gilead's history. Across daily and long-acting dosing, we are advancing a portfolio that will deliver new options for many years to come. The most near-term example is islatravir plus lenacapavir. We expect to file this year, and, if approved, this would be the first once-weekly oral treatment regimen for virally suppressed people with HIV. In Oncology, Trodelvy delivered another very strong quarter. Sales were up 42% year-over-year, and with growing demand across triple-negative and HR-positive/HER2-negative metastatic breast cancer, Trodelvy reached an approximately $2 billion annual run rate. In the third quarter, we received European approval of Trodelvy in combination with pembrolizumab for first-line PD-L1-positive metastatic triple-negative breast cancer, extending Trodelvy's benefits to patients earlier in treatment.
Frequently Asked Questions About GILD
When is Gilead Sciences's next earnings date?
Gilead Sciences's next earnings report is expected for Feb 8, 2027.
Did GILD beat earnings estimates last quarter?
Yes. Gilead Sciences reported EPS of $2.55 for the quarter ended Sep 30, 2026, above the $2.17 estimate, a 17.51% surprise.
What EPS do analysts expect from GILD next quarter?
The consensus EPS estimate for Gilead Sciences for the quarter ending Dec 31, 2026 is $1.22 from 23 analysts, with estimates from $0.90 to $2.28.
How often does GILD beat earnings estimates?
Gilead Sciences beat the EPS estimate in each of the last 11 quarters, with an average surprise of +12.01%.
GILD pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts